ARCHIVES

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Advisory Group, Other Cancer Meetings

February 22, 1985

OSCC Groups Send Four Concepts To NCI Board

September 13, 1985

NEJM Does About-Face, Issues Correction On CT Lung Cancer Screening Study.

April 4, 2008

Center Review By Panel, NCI Leading To Changes; Hammer Tells NCAB It Faces “Difficult Decision”

December 13, 1984

In Brief: Cancer Control Needs More Oncologists, DCT recruiting for Prestigious Combines Job

November 21, 1975

Massive New Radiation Research program Costing From $300-$400 Million Over 10 Years Suggested

February 11, 1977